Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$597.1M
355M shares
52-week range
$1.60 – $4.27
1% from low
Exchange
NASDAQ
ADRC
P/S (TTM)
0.8
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
www.evotec.comNo one on the platform currently holds EVO.
No tracked institution reports a position in EVO as of their last filing.
No one on the platform has traded EVO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -5.0% | 8.6% | ||||
| Profit Margin % | -13.1% | -7.4% | 2.1% | |||
| Free Cash Flow Margin % | -10.4% | -8.8% | 1.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $605M | -22.2% | $-0.65 | $-0.75–$-0.62 | — | 1 |
| 2027 | $724M | +19.6% | $-0.16 | $-0.18–$-0.15 | — | 1 |
| 2028 | $786M | +8.5% | $0.01 | $0.01–$0.01 | 139.2× | 1 |
| 2029 | $819M | +4.2% | $0.10 | $0.09–$0.11 | 17.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.05 | $-0.17 | -275.4% |
| 2026-05-06 | $-0.15 | $-0.46 | -209.5% |
| 2026-04-08 | $0.21 | $0.05 | -74.0% |
| 2025-11-05 | $-0.14 | $-0.14 | -1.4% |
| 2025-08-13 | $-0.18 | $-0.14 | +19.9% |
| 2025-05-06 | $-0.11 | $-0.15 | -37.1% |
| 2025-04-17 | $0.02 | $-0.12 | -768.2% |
| 2024-11-06 | $-0.08 |
| $-0.12 |
| -50.0% |
| — |
| PCRXPacira BioSciences, Inc. | $24.08 | -2.43% | $947M | — |
| PHVSPharvaris N.V. | $38.06 | -2.06% | $2.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$EVO Really good write-up that perfectly summarizes EVO's present situation. So if you want to bring your EVO knowledge up to date or just discover EVO, this is required reading. https://everyticker.com/quote/EVO/analysis/evotec-s-horizon-gamble-can-a-science-heavy-drug-discovery-partner-transform-into-a-profitable-platform-nasdaq-evo
View on StockTwits ↗
$EVO This is exactly why patience matters in trading. A lot of people want to jump in the moment a setup appears, but confirmation is everything. If you bought right when the previous post came out, you’d already be sitting on a ~30% loss within days. The chart is still showing weakness, and price action continues to suggest there may be more downside ahead. Good trades are not about catching every move. They’re about waiting for the right moment, protecting capital, and letting the chart prove the setup before taking a position.
View on StockTwits ↗
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
View on StockTwits ↗
$EVO around 11–12x earnings, which is unusually low for a company that still generates extremely high margins and strong cash flow..,
View on StockTwits ↗
$EVO Wall Street analysts place the consensus 12-month price target for Evotec SE (NASDAQ: EVO) at roughly $5.20 per share, indicating a potential upside of approximately +69% compared to current trading levels. Forecasts range widely, with a high estimate of $7.00 .
View on StockTwits ↗
$EVO -12% in pre-market following €116.1 Million Convertible Bond headline 🔻
View on StockTwits ↗
$EVO has appointed Dr. Ingrid Müller as Chief Operating Officer (COO), effective May 1, 2026. https://biotuesdays.com/2026/04/15/dr-ingrid-muller-joins-evotec-as-coo/
View on StockTwits ↗
$EVO Evotec Appoints Dr. Ingrid M ller as Chief Operating Officer https://marketwirenews.com/stock/evo/news/evotec-appoints-dr-ingrid-m-xfc-ller-as-chief-operat-6497978197933043.html?utm_source=stocktwits
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.